YDYunjie Dan

Yunjie Dan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yunjie Dan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of HLA‐DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e‐antigen seropositive chronic hepatitis B patients

    by Lin Cheng, Xiaowen Sun, Shun Tan, Wenting Tan, Yunjie Dan, Yi Zhou, Qing Mao, Guohong Deng

    Aim The reason why the majority of chronic hepatitis B (CHB) patients do not respond to conventional interferon (IFN)‐α or pegylated interferon (PEG IFN) treatment has not been formally demonstrated. The aim of this study was to investigate the association between single nucleotide polymorphisms (SNPs) and response to IFN‐α or PEG IFN therapy in Chinese patients with CHB. Methods Four SNPs among the HLA‐DPA1, HLA‐DPB1 (rs3077 and rs9277535) and IL28B (rs12979860 and rs8099917) regions were genotyped using the MGB‐TaqMan SNP genotyping assay in 144 hepatitis B e‐antigen (HBeAg) seropositive CHB patients who had received 6–12 months IFN‐α or PEG IFN treatment. Patients were classified as responders who achieved any of the four targets: (i) the loss of HBeAg; (ii) anti‐HBe seroconversion; (iii) suppression of hepatitis B virus (HBV) DNA level to below 3 log of baseline; and (iv) alanine aminotransferase normalization. Results By multivariate analysis at 6 months of therapy and 6 months post‐therapy, the results showed that rs3077‐GG genotype was independently associated with higher HBeAg loss rate and anti‐HBe seroconversion rate, and rs9277535‐GG genotype was independently associated with decline of HBV DNA level. However, we did not observe the significant association between SNP near IL28B and the response to IFN‐α or PEG IFN treatment. Conclusion This study suggested that HLA‐DPA1 and HLA‐DPB1 variants were significantly associated with HBeAg loss, anti‐HBe seroconversion and HBV DNA level suppression in HBeAg seropositive CHB patients who received IFN‐α or PEG IFN treatment.


  • Open Access

    Estrogen receptor alpha gene polymorphisms and risk of HBV-related acute liver failure in the Chinese population

    by Zehui Yan, Wenting Tan, Yunjie Dan, Wenli Zhao, Chunqing Deng, Yuming Wang, Guohong Deng

    Background: The sexual dimorphism of hepatitis B virus (HBV) -related liver diseases is related with estrogen and its receptors. Recent reports indicate that abnormal expression of estrogen receptor alpha (ESR1) may be a hallmark for the progression of liver disease and HBV carriers presenting variant ESR1 have an extremely aggressive clinical course. Here we examine whether the ESR1 polymorphisms or its haplotypes are related to HBV-related acute liver failure (ALF) risk among chronic HBV carriers in a Chinese population. Methods: A total of 1216 unrelated Han Chinese HBV carriers were recruited in this hospital-based case–control study, including 359 HBV surface antigen (HBsAg) carriers affected with ALF and 857 asymptomatic HBsAg carriers. Two ESR1 haplotype tagging polymorphisms, c.30 T > C (rs2077647) and c.453-397 T > C (rs2234693), were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Results: We observed a significantly increased susceptibility to HBV-ALF associated with the c.30 C allele (P = 8.65 × 10-4), c.453-397 C allele (5.37 × 10-4) and [c.30 C; c.453-397 C] haplotype (Dominant model, P =0.0004, odds ratio = 1.53, 95% CI 1.23 ~ 1.96) compared with the T alleles and [c.30 T; c.453-397 T] haplotype of c.30 T > C and c.453-397 T > C polymorphisms, respectively. Conclusions: Our study suggests that [c.30 C; c.453-397 C] hapotype may be a risk factor for genetic susceptibility to HBV-related ALF in the Chinese population. It also emphasizes the importance of ESR1 in the pathophysiology of HBV-related ALF on the population level.


    • 1 October 2011
      • Vol. 19  (10) , 793-4

    [Analysis of clinical correlated factors of primary carcinoma of the liver with and without cirrhosis].

    by Xiao-Wen Sun, Wen-Ting Tan, Shun Tan, Yun-Jie Dan, Sha-Sha Wang, Guo-Hong Deng

  • Association of TBX21 promoter polymorphisms with type 1 autoimmune hepatitis in a Chinese population

    by Song Chen, Wenli Zhao, Wenting Tan, Xiao Luo, Yunjie Dan, Zhonglan You, Xuemei Kuang, Yuming Wang, Guohong Deng


  • PP-082 A Cis-acting regulatory variation of estrogen receptor-α and the association with HBV-related liver diseases

    by Zehui Yan, Guohong Deng, Wenting Tan, Wenli Zhao, Yunjie Dan, Wen Chen, Yingzi Tang, Xia Zhou, Xiaohong Wang, Qing Mao, et al.

    • 1 February 2009
      • Vol. 17  (2) , 91-4

    [Analysis of the correlation between the pre-S1 antigen, pre-S2 antigen and DNA of hepatitis B virus in the serum of chronic hepatitis B patients undergoing nucleoside analogue therapy.].

    by Zhao-Xia Tan, Wen-Ting Tan, Ying-Zi Tang, Yun-Jie Dan, Guo-Hong Deng

    To investigate the dynamic correlation between pre-S1 antigen, pre-S2 antigen and HBV DNA in the serum of chronic hepatitis B (CHB) patients undergoing nucleoside analogue therapy. 12 CHB patients with transient virological response after lamivudine treatment, and 20 patients treated with adefovir for 5 years were recruited in this study. Serum samples were collected at four time points when HBV DNA fluctuated sharply during lamivudine treatment, and at 0, 8, 12, 28, 52, 104, 156, 208, 260 weeks following adefovir treatment. HBV DNA was quantified by real-time PCR, pre-S1 and pre-S2 antigens were detected by ELISA. The titers of pre-S1 and pre-S2 antigens were not correlated with the HBV DNA level in the serum of lamivudine treated patients. Only in one case of the adfovir treated patients, the decrease of pre-S1 and pre-S2 antigens was in parallel with the decrease of HBV DNA. Linear regression analysis indicated that neither pre-S1 antigen nor pre-S2 antigen was correlated with HBV DNA in the serum of lamivudine or adfovir treated patients (P more than 0.05). Our results indicate that the titers of pre-S1 and pre-S2 antigens are not correlated with the serum HBV DNA in CHB patients undergoing nucleoside analogue therapy. Neither pre-S1 nor pre-S2 is a good predictor for the outcome of nucleoside analogue treatment.

    • 1 July 2008
      • Vol. 16  (7) , 540-1

    [The influence of HBV genotypes on the therapeutic effects of lamivudine in chronic hepatitis B patients].

    by Wen-Ting Tan, Guo-Hong Deng, Yu-Ming Wang, Yun-Jie Dan, Xue-Mei Kuang